{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:44:07Z","timestamp":1785408247303,"version":"3.56.0"},"reference-count":152,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respir Res Clin Pract"],"published-print":{"date-parts":[[2026,2,10]]},"abstract":"<jats:p>Objective: There has been limited research comparing the inflammatory characteristics\nof moderate and severe asthma in Brazil. To describe and compare the phenotypes\nof moderate asthma (MA) and severe asthma (SA) in Brazilian patients. Methods: In\nthis cross-sectional study, we defined SA per the 2014 European Respiratory Society\/\nAmerican Thoracic Society criteria and MA per the 2018 GINA criteria. No participants\nhad other lung diseases, recent respiratory infection, or a recent exacerbation. Asthma\nwas characterized and phenotyped by using validated tests. Results: Compared to MA\n(n = 55), SA (n = 51) had more hospital (p &lt; 0.001) and ICU admissions (p = 0.01), worse\nfixed airflow limitation (FEV1\/FVC post-BD = 0.61; p &lt; 0.001), poorer asthma control (p =\n0.001), and reduced quality of life. However, this was not associated with higher activity\nof inflammation as measured by IS and Beos counts, which were similar. Of the 19\npatients with MA who reported \u2265 1 exacerbation in the last year, 12 (63.1%) had residual\neosinophilia in induced sputum, compared with 22 (62.8%) of the 35 such patients with\nSA. The correlation between IS eosinophils and Beos was strong (rs = 0.75, R\u00b2 = 0.35;\np &lt; 0.001), though agreement was moderate. T2 high phenotypes were predominant\n(76% in both groups). However, in the MA group, the prevalence of eosinophilic\nallergic asthma was higher than that of nonallergic asthma (56% vs 20%, p&lt;0.001). In\nthe SA group, those phenotypes had a similar prevalence (41% and 35% respectively).\nConclusions: Our analysis indicates that most subjects with SA or MA have the T2-high\nasthma phenotype, primarily allergic eosinophilic, in MA. Significant residual eosinophilic\nairway inflammation and recurrent exacerbations in some patients with MA suggest the\nneed for further research on the optimal timing for phenotyping and biologic treatments\nacross different levels of asthma severity<\/jats:p>","DOI":"10.36416\/1806-3756\/e20240354","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:07:29Z","timestamp":1774292849000},"page":"e20240354","source":"Crossref","is-referenced-by-count":0,"title":["Phenotyping moderate asthma earlier by analyzing induced sputum eosinophils, blood eosinophils, and atopy: a cross-sectional comparison with severe asthma"],"prefix":"10.36416","author":[{"given":"Marcia","family":"Margaret Menezes Pizzichini1,2","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/041akq887","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Federal de Santa Catarina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane","family":"Cinara Rocha1,2","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/041akq887","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Federal de Santa Catarina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Pizzichini1,2","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/041akq887","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Federal de Santa Catarina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22288","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"ref0","unstructured":"1. Thamrin C, Frey U, Kaminsky DA, Reddel HK, Seely AJ, Suki B, et al."},{"key":"ref1","unstructured":"Systems Biology and Clinical Practice in Respiratory Medicine. The"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Twain Shall Meet. Am J Respir Crit Care Med. 2016;194(9):1053-","DOI":"10.1164\/rccm.201511-2288PP"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"1061. https:\/\/doi.org\/10.1164\/rccm.201511-2288PP","DOI":"10.1164\/rccm.201511-2288PP"},{"key":"ref4","unstructured":"2. Ray A, Camiolo M, Fitzpatrick A, Gauthier M, Wenzel SE. Are We"},{"key":"ref5","unstructured":"Meeting the Promise of Endotypes and Precision Medicine in"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Asthma? Physiol Rev. 2020;100(3):983-1017. https:\/\/doi.org\/10.1152\/","DOI":"10.1152\/physrev.00023.2019"},{"key":"ref7","unstructured":"physrev.00023.2019"},{"key":"ref8","unstructured":"3. Lambrecht BN, Hammad H, Fahy JV. The Cytokines of Asthma."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Immunity. 2019;50(4):975-991. https:\/\/doi.org\/10.1016\/j.","DOI":"10.1016\/j.immuni.2019.03.018"},{"key":"ref10","unstructured":"immuni.2019.03.018"},{"key":"ref11","unstructured":"4. Quirce S, Heffler E, Nenasheva N, Demoly P, Menzies-Gow A,"},{"key":"ref12","unstructured":"Moreira-Jorge A, et al. Revisiting Late-Onset Asthma: Clinical"},{"key":"ref13","unstructured":"Characteristics and Association with Allergy. J Asthma Allergy."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"2020;13:743-752. https:\/\/doi.org\/10.2147\/JAA.S282205","DOI":"10.2147\/JAA.S282205"},{"key":"ref15","unstructured":"5. Peters MC, Wenzel SE. Intersection of biology and therapeutics: type 2"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"targeted therapeutics for adult asthma. Lancet. 2020;395(10221):371-","DOI":"10.1016\/S0140-6736(19)33005-3"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"383 https:\/\/doi.org\/10.1016\/S0140-6736(19)33005-3","DOI":"10.1016\/S0140-6736(19)33005-3"},{"key":"ref18","unstructured":"6. Busse WW, Fang J, Marvel J, Tian H, Altman P, Cao H. Uncontrolled"},{"key":"ref19","unstructured":"asthma across GINA treatment steps 2-5 in a large US patient"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"cohort. J Asthma. 2022;59(5):1051-1062 https:\/\/doi.org\/10.1080\/02","DOI":"10.1080\/02770903.2021.1897834"},{"key":"ref21","unstructured":"770903.2021.1897834"},{"key":"ref22","unstructured":"7. Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML,"},{"key":"ref23","unstructured":"Bel EH. The prevalence of severe refractory asthma. J Allergy"},{"key":"ref24","unstructured":"Clin Immunol. 2015;135(4):896-902. https:\/\/doi.org\/10.1016\/j."},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"jaci.2014.08.042","DOI":"10.1088\/1475-7516\/2014\/08\/042"},{"key":"ref26","unstructured":"8. Carvalho-Pinto RM, Can\u00e7ado JED, Pizzichini MMM, Fiterman J,"},{"key":"ref27","unstructured":"Rubin AS, Cerci Neto A, et al. 2021 Brazilian Thoracic Association"},{"key":"ref28","unstructured":"recommendations for the management of severe asthma. J Bras"},{"key":"ref29","unstructured":"Pneumol. 2021;47(6):e20210273. https:\/\/doi.org\/10.36416\/1806-"},{"key":"ref30","unstructured":"3756\/e20210273"},{"key":"ref31","unstructured":"9. Lommatzsch M, Buhl R, Canonica GW, Ribas CD, Nagase"},{"key":"ref32","unstructured":"H, Brusselle GG, et al. Pioneering a paradigm shift in asthma"},{"key":"ref33","unstructured":"management: remission as a treatment goal. Lancet Respir Med."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"2024;12(2):96-99. https:\/\/doi.org\/10.1016\/S2213-2600(23)00415-0","DOI":"10.1016\/S2213-2600(23)00415-0"},{"key":"ref35","unstructured":"10. Bourdin A, Brusselle G, Couillard S, Fajt ML, Heaney LG, Israel E, et"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"al. Phenotyping of Severe Asthma in the Era of Broad-Acting AntiAsthma Biologics. J Allergy Clin Immunol Pract. 2024;12(4):809-823.","DOI":"10.1016\/j.jaip.2024.01.023"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaip.2024.01.023","DOI":"10.1016\/j.jaip.2024.01.023"},{"key":"ref38","unstructured":"11. Nair P, Surette MG, Virchow JC. Neutrophilic asthma: misconception"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"or misnomer? Lancet Respir Med. 2021;9(5):441-443. https:\/\/doi.","DOI":"10.1016\/S2213-2600(21)00023-0"},{"key":"ref40","unstructured":"org\/10.1016\/S2213-2600(21)00023-0"},{"key":"ref41","unstructured":"12. Global Initiative for Asthma [homepage on the internet]. Bethesda:"},{"key":"ref42","unstructured":"Global Initiative for Asthma; c2021 [cited 2024 October 13]. Global"},{"key":"ref43","unstructured":"Strategy for Asthma Management and Prevention (2024 update)."},{"key":"ref44","unstructured":"Available from: https:\/\/ginasthma.org\/2024-report\/"},{"key":"ref45","unstructured":"13. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch"},{"key":"ref46","unstructured":"M, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal"},{"key":"ref47","unstructured":"antibody, as add-on treatment for patients with severe, uncontrolled,"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"eosinophilic asthma (CALIMA): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet. 2016;388(10056):2128- 2141.8","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(16)31322-8","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"ref50","unstructured":"14. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker"},{"key":"ref51","unstructured":"P, et al. Efficacy and safety of benralizumab for patients with severe"},{"key":"ref52","unstructured":"asthma uncontrolled with high-dosage inhaled corticosteroids and"},{"key":"ref53","unstructured":"long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre,"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115-","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"2127. https:\/\/doi.org\/10.1016\/S0140-6736(16)31324-1","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"ref56","unstructured":"15. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al."},{"key":"ref57","unstructured":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Asthma. N Engl J Med. 2018;378(26):2486-2496. https:\/\/doi.","DOI":"10.1056\/NEJMoa1804092"},{"key":"ref59","unstructured":"org\/10.1056\/NEJMoa1804092"},{"key":"ref60","unstructured":"16. Shackleford A, Heaney LG, Redmond C, McDowell PJ, Busby J."},{"key":"ref61","unstructured":"Clinical remission attainment, definitions, and correlates among"},{"key":"ref62","unstructured":"patients with severe asthma treated with biologics: a systematic"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"review and meta-analysis. Lancet Respir Med. 2025;13(1):23-34.","DOI":"10.1016\/S2213-2600(24)00293-5"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S2213-2600(24)00293-5","DOI":"10.1016\/S2213-2600(24)00293-5"},{"key":"ref65","unstructured":"17. Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin"},{"key":"ref66","unstructured":"P, et al. Biologics (mepolizumab and omalizumab) induced remission"},{"key":"ref67","unstructured":"in severe asthma patients. Allergy. 2024;79(2):384-392. https:\/\/doi."},{"key":"ref68","unstructured":"org\/10.1111\/all.15867"},{"key":"ref69","unstructured":"18. Park SY, Fowler S, Shaw DE, Adcock IM, Sousa AR, Djukanovic R,"},{"key":"ref70","unstructured":"et al. Comparison of Asthma Phenotypes in Severe Asthma Cohorts"},{"key":"ref71","unstructured":"(SARP, U-BIOPRED, ProAR and COREA) From 4 Continents. Allergy"},{"key":"ref72","unstructured":"Asthma Immunol Res. 2024;16(4):338-352. https:\/\/doi.org\/10.4168\/"},{"key":"ref73","unstructured":"aair.2024.16.4.338"},{"key":"ref74","unstructured":"19. Freitas PD, Xavier RF, McDonald VM, Gibson PG, Cordova-Rivera L,"},{"key":"ref75","unstructured":"Furlanetto KC, et al. Identification of asthma phenotypes based on"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"extrapulmonary treatable traits. Eur Respir J. 2021;57(1):2000240.","DOI":"10.1183\/13993003.00240-2020"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1183\/13993003.00240-2020","DOI":"10.1183\/13993003.00240-2020"},{"key":"ref78","unstructured":"20. Athanazio R, Stelmach R, Antila M, Souza-Machado A, Arruda"},{"key":"ref79","unstructured":"LK, Cerci Neto A, et al. Prevalence of the eosinophilic phenotype"},{"key":"ref80","unstructured":"among severe asthma patients in Brazil: the BRAEOS study. J Bras"},{"key":"ref81","unstructured":"Pneumol. 2022;48(3):e20210367. https:\/\/doi.org\/10.36416\/1806-"},{"key":"ref82","unstructured":"3756\/e20210367"},{"key":"ref83","unstructured":"21. de Carvalho-Pinto RM, Cukier A, Angelini L, Antonangelo L, Mauad T,"},{"key":"ref84","unstructured":"Dolhnikoff M, et al. Clinical characteristics and possible phenotypes"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"of an adult severe asthma population. Respir Med. 2012;106(1):47-","DOI":"10.1016\/j.rmed.2011.08.013"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"56. https:\/\/doi.org\/10.1016\/j.rmed.2011.08.013","DOI":"10.1016\/j.rmed.2011.08.013"},{"key":"ref87","unstructured":"22. ATS. Standardization of Spirometry, 1994 Update. American Thoracic"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Society. Am J Respir Crit Care Med. 1995;152(3):1107-36. https:\/\/","DOI":"10.1164\/ajrccm.152.3.7663792"},{"key":"ref89","unstructured":"doi.org\/10.1164\/ajrccm.152.3.7663792"},{"key":"ref90","unstructured":"23. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et"},{"key":"ref91","unstructured":"al. International ERS\/ATS guidelines on definition, evaluation and"},{"key":"ref92","unstructured":"treatment of severe asthma. Eur Respir J. 2014;43(2):343-73. https:\/\/"},{"key":"ref93","unstructured":"doi.org\/10.1183\/09031936.00202013"},{"key":"ref94","unstructured":"24. Global Initiative for Asthma [homepage on the Internet]. Bethesda:"},{"key":"ref95","unstructured":"Global Initiative for Asthma; c2018 [cited 2024 Nov 01]. Global"},{"key":"ref96","unstructured":"Strategy for Asthma Management and Prevention (2018 update)."},{"key":"ref97","unstructured":"[Adobe Acrobat document, 201p.]. Available from: www.ginasthma."},{"key":"ref98","unstructured":"org"},{"key":"ref99","unstructured":"25. Gell P, Coombs R, Lachmann P. Clinical aspects of immunology. 3rd"},{"key":"ref100","unstructured":"ed. Oxford Philadelphia: Blackwell Scientific Publications; 1975."},{"key":"ref101","unstructured":"26. Juniper EF, O\u2019Byrne PM, Guyatt GH, Ferrie PJ, King DR."},{"key":"ref102","unstructured":"Development and validation of a questionnaire to measure asthma"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"control. Eur Respir J. 1999;14(4):902-7. https:\/\/doi.org\/10.1034\/","DOI":"10.1034\/j.1399-3003.1999.14d29.x"},{"key":"ref104","unstructured":"j.1399-3003.1999.14d29.x"},{"key":"ref105","unstructured":"27. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation"},{"key":"ref106","unstructured":"of a standardized version of the Asthma Quality of Life"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Questionnaire. Chest. 1999;115(5):1265-70. https:\/\/doi.org\/10.1378\/","DOI":"10.1378\/chest.115.5.1265"},{"key":"ref108","unstructured":"chest.115.5.1265"},{"key":"ref109","unstructured":"28. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal"},{"key":"ref110","unstructured":"important change in a disease-specific Quality of Life Questionnaire."},{"key":"ref111","unstructured":"J Clin Epidemiol. 1994;47(1):81-7. https:\/\/doi.org\/10.1016\/0895-"},{"key":"ref112","unstructured":"4356(94)90036-1"},{"key":"ref113","unstructured":"29. Crapo RO, Morris AH, Gardner RM. Reference spirometric values"},{"key":"ref114","unstructured":"using techniques and equipment that meet ATS recommendations."},{"key":"ref115","unstructured":"Am Rev Respir Dis. 1981;123(6):659-664. https:\/\/doi.org\/10.1164\/"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"arrd.1981.123.6.659","DOI":"10.1016\/0005-2744(81)90276-X"},{"key":"ref117","unstructured":"30. Juniper EF, Cockcroft DW, Hargreave FE. Histamine and"},{"key":"ref118","unstructured":"Methacholine Inhalation Tests: A Laboratory Tidal Breathing Protocol."},{"key":"ref119","unstructured":"Lund, Sweden: Astra Draco AB; 1994."},{"key":"ref120","unstructured":"31. Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM,"},{"key":"ref121","unstructured":"Squillace D, et al. Indices of airway inflammation in induced sputum:"},{"key":"ref122","unstructured":"reproducibility and validity of cell and fluid-phase measurements."},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"Am J Respir Crit Care Med. 1996;154(2 Pt 1):308-17. https:\/\/doi.","DOI":"10.1164\/ajrccm\/154.2_Pt_2.S1"},{"key":"ref124","unstructured":"org\/10.1164\/ajrccm.154.2.8756799"},{"key":"ref125","unstructured":"32. Westerhof GA, Korevaar DA, Amelink M, de Nijs SB, de Groot JC,"},{"key":"ref126","unstructured":"Wang J, et al. Biomarkers to identify sputum eosinophilia in different"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"adult asthma phenotypes. Eur Respir J. 2015;46(3):688-96. https:\/\/","DOI":"10.1183\/09031936.00012415"},{"key":"ref128","unstructured":"doi.org\/10.1183\/09031936.00012415"},{"key":"ref129","unstructured":"33. Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, MenziesGow AN, et al. Characterization of Severe Asthma Worldwide:"},{"key":"ref130","unstructured":"Data From the International Severe Asthma Registry. Chest."},{"key":"ref131","doi-asserted-by":"crossref","unstructured":"2020;157(4):790-804. Erratum in: Chest. 2021;160(5):1989. https:\/\/","DOI":"10.1016\/j.chest.2021.09.031"},{"key":"ref132","unstructured":"doi.org\/10.1016\/j.chest.2021.09.030"},{"key":"ref133","unstructured":"34. Teague WG, Phillips BR, Fahy JV, Wenzel SE, Fitzpatrick AM, Moore"},{"key":"ref134","unstructured":"WC, et al. Baseline Features of the Severe Asthma Research Program"},{"key":"ref135","unstructured":"(SARP III) Cohort: Differences with Age. J Allergy Clin Immunol"},{"key":"ref136","doi-asserted-by":"crossref","unstructured":"Pract. 2018:545-554.e4. https:\/\/doi.org\/10.1016\/j.jaip.2017.05.032","DOI":"10.1016\/j.jaip.2017.05.032"},{"key":"ref137","unstructured":"35. Meulmeester FL, Mailhot-Larouche S, Celis-Preciado C, LemairePaquette S, Ramakrishnan S, Wechsler ME, et al. Inflammatory and"},{"key":"ref138","unstructured":"clinical risk factors for asthma attacks (ORACLE2): a patient-level"},{"key":"ref139","unstructured":"meta-analysis of control groups of 22 randomised trials. Lancet"},{"key":"ref140","unstructured":"Respir Med. 2025:S2213-2600(25)00037-2. https:\/\/doi.org\/10.1016\/"},{"key":"ref141","unstructured":"S2213-2600(25)00037-2"},{"key":"ref142","unstructured":"36. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight:"},{"key":"ref143","unstructured":"Eosinophilic airway inflammation in nonallergic asthma. Nat Med."},{"key":"ref144","doi-asserted-by":"crossref","unstructured":"2013;19(8):977-9. https:\/\/doi.org\/10.1038\/nm.3300","DOI":"10.1038\/nm.3300"},{"key":"ref145","unstructured":"37. Hussain M, Liu G. Eosinophilic Asthma: Pathophysiology and"},{"key":"ref146","doi-asserted-by":"crossref","unstructured":"Therapeutic Horizons. Cells. 2024;13(5):384. https:\/\/doi.org\/10.3390\/","DOI":"10.3390\/cells13050384"},{"key":"ref147","unstructured":"cells13050384"},{"key":"ref148","unstructured":"38. Mailhot-Larouche S, Celis-Preciado C, Heaney LG, Couillard S."},{"key":"ref149","unstructured":"Identifying super-responders: A review of the road to asthma"},{"key":"ref150","doi-asserted-by":"crossref","unstructured":"remission. Ann Allergy Asthma Immunol 2025 (134);31-45. https:\/\/","DOI":"10.1016\/j.anai.2024.09.023"},{"key":"ref151","unstructured":"doi.org\/10.1016\/j.anai.2024.09.023"}],"container-title":["Respiratory Research &amp; Clinical Practice"],"original-title":[],"link":[{"URL":"https:\/\/www.ithenticate.com\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:07:41Z","timestamp":1774292861000},"score":1,"resource":{"primary":{"URL":"https:\/\/rrcpjournal.org\/article\/phenotyping-moderate-asthma-earlier-by-analyzing-induced-sputum-eosinophils-blood-eosinophils-and-atopy-a-cross-sectional-comparison-with-severe-asthma\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":152,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20240354","relation":{},"ISSN":["3086-3910"],"issn-type":[{"value":"3086-3910","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"article-number":"2024-0354"}}